New Landmark Studies on Sweet Taste and Low/No Calorie Sweeteners

Key Takeaways

• LNCS aid weight‑loss maintenance versus sugar‑only diets.
• No adverse cardiometabolic effects observed after 12‑month use.
• In diabetics, LNCS drinks improved HbA1c versus water.
• Sweetness exposure did not shift taste preference or intake.
• Individualized, sugar‑replacement use recommended for diet quality.

Summary

Three new large‑scale randomized trials have filled a critical evidence gap on low‑ and no‑calorie sweeteners (LNCS). The EU‑funded SWEET study showed that replacing sugar with LNCS helped participants maintain 1.6 kg more weight loss over 12 months without cardiometabolic harm. The SODAS trial found that habitual LNCS‑sweetened beverage consumers with type‑2 diabetes experienced a modest HbA1c advantage over those who switched to water. Finally, the Sweet Tooth trial demonstrated that varying dietary sweetness exposure did not alter sweet‑taste preferences, calorie intake, or body weight.

Pulse Analysis

Conflicting global guidance on low‑ and no‑calorie sweeteners has left clinicians uncertain, with the WHO issuing a conditional recommendation against their use for weight control, while agencies such as the UK SACN and the American Diabetes Association view them as useful adjuncts. The divergence stems largely from differing emphasis on observational versus randomized evidence, and from the limited duration of earlier trials. The emergence of three rigorously designed, long‑term RCTs now provides the data needed to reconcile these positions, offering a clearer picture of LNCS effects in real‑world dietary patterns.

The SWEET project, the largest weight‑maintenance trial to date, demonstrated that participants who substituted sugar with LNCS maintained an additional 1.6 kg of weight loss after a year, with the gap widening to nearly 4 kg among highly compliant individuals. Importantly, metabolic markers—including glucose, insulin, and cardiovascular risk factors—remained unchanged, dispelling concerns about hidden harms. In the SODAS trial, adults with type‑2 diabetes who continued consuming LNCS‑sweetened drinks showed a modest but statistically significant improvement in HbA1c compared with those who switched to water, suggesting that for habitual consumers, LNCS may support glycaemic stability without compromising weight.

The Sweet Tooth trial adds a behavioral dimension, revealing that adult sweet‑taste preferences are remarkably stable regardless of low, regular, or high sweetness exposure over six months. This finding underscores that strategies focused solely on reducing dietary sweetness are unlikely to shift preferences or reduce caloric intake. For practitioners, the combined evidence points to a nuanced, patient‑centred approach: use LNCS as a sugar replacement within a balanced, low‑sugar diet, tailor recommendations to individual consumption patterns, and set realistic expectations about taste adaptation. Future research should explore longer follow‑up periods and diverse populations to further refine guidance.